Skip to main content
SpringerLink
Log in

Rifaximin is a safe and effective antibacterial for treating noninvasive traveller’s diarrhoea

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Notes

  1. Also registered as Flonorm®, Lormyx®, Redactiv®, Rifacol®, Spiraxin® and Zaxine®. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Ericsson CD. Travellers’ diarrhoea. Int J Antimicrob Agents 2003 Feb; 21(2): 116–24

    Article  PubMed  CAS  Google Scholar 

  2. Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers’ diarrhea. J Travel Med 2001 Dec; 8Suppl. 2: S26–30

    Article  PubMed  CAS  Google Scholar 

  3. Casburn-Jones AC, Farthing MJG. Traveler’s diarrhea. Gastroenterol Hepatol 2004; 19(6): 610–8

    Article  Google Scholar 

  4. DuPont HL. Travellers’ diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006; 66(3): 303–14

    Article  PubMed  CAS  Google Scholar 

  5. Okhuysen P, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774–8

    Article  PubMed  Google Scholar 

  6. Caeiro JP, DuPont HL. Management of travellers’ diarrhoea. Drugs 1998; 56(1): 73–81

    Article  PubMed  CAS  Google Scholar 

  7. DuPont HL, Mattila L. Antimicrobial treatment: an algorithmic approach. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers’ diarrhea. Hamilton (ONT): BC Decker Inc, 2003: 227–37

    Google Scholar 

  8. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller’s diarrhoea. Drugs 2005; 65(12): 1697–713

    Article  PubMed  CAS  Google Scholar 

  9. Gascon J, Corachan M. Aetiology, epidemiology, and management of traveller’s diarrhoea. Rev Med Microbiol 2003; 14(3): 73–8

    Article  Google Scholar 

  10. Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers’ diarrhoea. Drug Saf 2006; 29(3): 201–7

    Article  PubMed  CAS  Google Scholar 

  11. Salix Pharmaceuticals Inc. Xifaxin (rifaximin) prescribing information. Morrisville (NC), 2005 Oct

  12. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 Dec 1; 33: 1807–15

    Article  PubMed  CAS  Google Scholar 

  13. FDA. Medical review: application number 21–361. Clinical study RFID3001 [online]. Available from URL: http://www.fda.gov/cder [Accessed 2006 Apr 26]

  14. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 May; 98: 1073–8

    Article  PubMed  CAS  Google Scholar 

  15. Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004 Feb; 2(2): 135–8

    Article  PubMed  CAS  Google Scholar 

  16. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 Nov; 10(11): 1009–11

    Article  PubMed  CAS  Google Scholar 

  17. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998; 59(6): 708–14

    Article  PubMed  CAS  Google Scholar 

  18. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12(12): 979–81

    PubMed  Google Scholar 

  19. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005 May 17; 142(10): 805–12

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rifaximin is a safe and effective antibacterial for treating noninvasive traveller’s diarrhoea. Drugs Ther. Perspect 22, 1–5 (2006). https://doi.org/10.2165/00042310-200622070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622070-00001

Search

Navigation